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Atypical hemolytic uremic syndrome (aHUS) is a rare, possibly
life-threatening disease characterized by platelet activation,
hemolysis and thrombotic microangiopathy (TMA) leading to
renal and other end-organ damage. We originally conducted
two phase 2 studies (26 weeks and 1 year) evaluating
eculizumab, a terminal complement inhibitor, in patients
with progressing TMA (trial 1) and those with long duration
of aHUS and chronic kidney disease (trial 2). The current
analysis assessed outcomes after 2 years (median eculizumab
exposure 100 and 114 weeks, respectively). At all scheduled
time points, eculizumab inhibited terminal complement
activity. In trial 1 with 17 patients, the platelet count was
significantly improved from baseline, and hematologic
normalization was achieved in 13 patients at week 26, and in
15 patients at both 1 and 2 years. The estimated glomerular
filtration rate (eGFR) was significantly improved compared
with baseline and year 1. In trial 2 with 20 patients, TMA
event-free status was achieved by 16 patients at week 26, 17
patients at year 1, and 19 patients at year 2. Criteria for
hematologic normalization were met by 18 patients at each
time point. Improvement of 15ml/min per 1.73m2 or more in
eGFR was achieved by 1 patient at week 26, 3 patients at 1
year, and 8 patients at 2 years. The mean change in eGFR was
not significant compared with baseline, week 26, or year 1.
Eculizumab was well tolerated, with no new safety concerns
or meningococcal infections. Thus, a 2-year analysis found
that the earlier clinical benefits achieved by eculizumab
treatment of aHUS were maintained at 2 years of follow-up.
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Atypical hemolytic uremic syndrome (aHUS) is a rare,
progressive, and possibly life-threatening disease of chronic,
uncontrolled complement activation, which affects patients
of all ages.1 aHUS is caused by dysregulation of the comple-
ment alternative pathway, leading to persistent cleavage of
complement protein C5, generation of proinflammatory C5a
and lytic C5b proteins, and the formation of the membrane
attack complex (C5b–9), which in turn leads to endothelial
cell activation, injury, and death.1–3 Patients with comple-
ment alternative pathway dysregulation are at lifelong
risk of thrombocytopenia, hemolysis, and renal impairment
that may also occur with extrarenal (i.e., neurological,
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cardiovascular, pulmonary, and gastrointestinal) organ
damage.1,4,5 Mutations in complement genes (e.g., CFH,
MCP, CFI, CFB, and C3) or complement factor H (CFH)
autoantibodies are identified in B50–70% of patients with
aHUS.4,6,7 Components of the coagulation pathway can also
modulate complement activation, and abnormalities in genes
encoding thrombomodulin (THBD/CD146) and plasmino-
gen (PLG)8,9 have been identified in small numbers of
patients. Rare cases of thrombotic microangiopathy (TMA)
are caused by recessive diacylglycerol kinase e (DGKE) muta-
tions;10 thus far, instances have been limited to infants o1
year of age, and have not been reported in adolescent- and
adult-onset aHUS. Although TMA complications observed in
DGKE mutation carriers indicate complement-independent
pathogenesis,10 a recent report identified a consanguineous
family with DGKE mutations and evidence of significantly
decreased C3 levels.11
Plasma exchange/plasma infusion (PE/PI) has historically
been used to manage aHUS, yet 67% of adult patients required
dialysis or died within 3 years, with variations in outcome by
genotype.6 Registry and observational studies have
demonstrated mortality rates of 8% at the first manifestation
and 11% at 3 years of follow-up in one series,6 and 2% in
adults and 8% in children at X45 months of follow-up in
another series.4 In addition, many patients with aHUS require
kidney transplantation6 but experience high rates (68%) of
post-transplant recurrence of TMA leading to graft failure;
rates vary by genotype but graft failure occurs inB70% within
Trial 1 Trial 2
Clinical diagnosis of aHUS witha: Clinical diagnosis of aHUS witha:
Progressing TMAb
17 Patients were screened
17 Were treated with eculizumab
15 Completed 26 weeks of treatment
1 Did not continue
into extension phase
19 Entered extension phase
20 Completed 26 weeks of treatment
20 Were treated with eculizumab
2 Were ineligible
1 Withdrew consent
23 Patients were screened
26-Week
treatment period
Extension
Phase
No platelet count decrease >25%
during the 8-week observation period
≥1 PE/PI session every 2 weeks, but
≤3 times per week for ≥8 weeks
13 Entered extension phase
1 Diedd (unrelated to
eculizumab
treatment)
2 Transitioned to
commercial
eculizumab
16 Continued extension phase to data
cutoff for 2-year analysis
(median duration, 114 weeks)e
5 Continued extension phase to data cutoff
for 2-year analysis
(median duration, 100 weeks)e
2 Did not continue
into extension phase
2 Withdrewc (2 with
AEs of worsening of
renal function)
6 Transitioned to
commercial
eculizumab
2 Withdrew
(1 protocol violation;
1 AE unrelated to
eculizumab)
≥4 PE/PI sessions in the week before
screening
Figure 1 | Patient disposition in trial 1 and trial 2. aAdditional inclusion and exclusion criteria were reported previously.21 bMeasured by low
platelet count (o150109/l) and a decrease of at least 25% lower than the average of three measures before the most recent TMA
complication. cBoth patients who withdrew during the extension study had a history of kidney transplant, poor renal function, and CKD
at the start of eculizumab treatment. These patients discontinued from the study after 67 and 82 weeks of treatment because of worsening
of severe CKD due to aHUS before eculizumab initiation. dThe patient was hospitalized for pyrexia; while hospitalized, the patient experienced
intestinal hemorrhage (distal ileum), which was considered a severe adverse event unrelated to eculizumab. The exact cause of the
intestinal hemorrhage remains unknown. The patient died 37 days after admission. ePatients may have had greater than 104 weeks of data at
the time of the cutoff. AE, adverse event; aHUS, atypical hemolytic uremic syndrome; CKD, chronic kidney disease; PE/PI, plasma exchange/
plasma infusion; TMA, thrombotic microangiopathy.
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5 years.12 Thus, although PE/PI may temporarily maintain
hematologic parameters, it does not inhibit the underlying
complement-mediated pathogenic mechanism of TMA,4,6,13,14
it does not block the terminal complement pathway, or it does
not efficiently prevent progression of tissue damage and
substantial morbidity and mortality.
Eculizumab (Soliris), the only approved treatment for
aHUS,15,16 is a humanized monoclonal antibody that binds
with high affinity to the human C5 complement protein and
blocks the formation of proinflammatory C5a and lytic
C5b.7,17–20 The efficacy and safety of eculizumab were
demonstrated in two prospective 26-week phase 2 studies
with 1-year extension phases: one in patients with aHUS with
clinical evidence of progressing TMA (trial 1; N¼ 17;
ClinicalTrials.gov numbers NCT00844545 (adults) and
NCT00844844 (adolescents)), and one in patients with
aHUS with long duration of disease and chronic kidney
damage receiving prolonged PE/PI (trial 2; N¼ 20;
ClinicalTrials.gov numbers NCT00838513 (adults) and
NCT00844428 (adolescents)).21 In both studies, eculizumab
inhibited complement activation within 1 h of the first
dose. Treatment resulted in significant improvements in
platelet count and renal function by 26 weeks (primary
analysis) and at the 1-year data cutoff. In addition,
patients treated with eculizumab did not have additional
TMA events, and PE/PI and dialysis were decreased or
eliminated.
Longer-term results are needed to establish the ongoing
efficacy and safety of eculizumab. Here we present outcomes
after 2 years of eculizumab therapy in patients with aHUS in
trial 1 and trial 2.
RESULTS
Patients
In trial 1, 17 patients (16 adults and one adolescent) with
aHUS and progressing TMAwere enrolled and 13 entered the
extension phase (Figure 1). At the 2-year data cutoff, 11
patients remained on eculizumab (five on study drug in the
trial; six transitioned to commercial eculizumab) and two
had withdrawn due to worsening renal function. The median
(range) duration of eculizumab exposure in trial 1 was 100
(2–145) weeks. In trial 2, 20 patients (15 adults and five
adolescents) were enrolled in and completed the initial 26-
week study. Nineteen patients entered the extension period
and continued eculizumab treatment for X78 weeks
(Figure 1). At the 2-year data cutoff, 18 patients remained
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Figure 2 | Effect of eculizumab on serum complement inhibition over 2 years of treatment in trial 1 and trial 2. Results from a
pharmacodynamic assay that quantified serum complement activity by measuring the degree of hemolysis, as determined by means of
a spectrophotometer. Inhibition of complement activity is indicated by 20% or lower hemolysis. Bars represent s.e.
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on eculizumab (16 on study drug in the trial, and two
transitioned to commercial eculizumab). The median (range)
duration of eculizumab exposure in trial 2 was 114 (26–129)
weeks. In both trials, data were not available after patients
transferred to commercial eculizumab. Terminal complement
activity was sufficiently inhibited at all scheduled time points
over 2 years in both studies (Figure 2).
Baseline demographics and disease characteristics were
previously reported and are summarized in Table 1. The
median time from onset of the current clinical manifestation
of aHUS to screening for the trial was 0.8 months in trial 1
and 8.6 months in trial 2. PE/PI was received by 17 patients
(100%) in trial 1 and by 20 patients (100%) in trial 2 before
the initiation of eculizumab, and estimated glomerular
filtration rate (eGFR) was o60ml/min per 1.73m2 in 17
(100%) and 18 patients (90%), respectively. Six patients
(35%) in trial 1 and two patients (10%) in trial 2 were on
dialysis before the first dose of eculizumab; in trial 1, 5
patients (29%) were on dialysis at the initiation of therapy.
The median (range) duration of dialysis during the current
manifestation was 22 (1 27) days in trial 1 and 625
(120 1129) days in trial 2. In trial 1, six patients (35%) had
one current kidney transplant and one patient (6%) had two
transplants. In trial 2, three patients (15%) had one current
transplant, three patients (15%) had two transplants, and two
patients (10%) had four transplants each.
Primary end points
All efficacy outcomes, calculated based on the intent-to-treat
populations and defined in Table 2,22–25 are reported in Table 3.
In trial 1, eculizumab treatment was associated with a
significant increase in platelet count from baseline at week 26
(Po0.001), 1 year (Po0.001), and at the 2-year cutoff
(Pp0.001; Figure 3), indicating the inhibition of comple-
ment-mediated TMA throughout treatment. Platelet count
was normalized in 14 patients (82%) at 26 weeks and in 15
patients (88%) at the 1- and 2-year cutoffs. Criteria for
hematologic normalization were met by 13 patients (76%) at
week 26 and by 15 patients (88%) at the 1- and 2-year
cutoffs. The two patients who did not achieve hematologic
Table 1 | Baseline demographics and disease characteristics
Parameter Trial 1 (N¼ 17) Trial 2 (N¼ 20)
Age, years, median (range) 28 (17–68) 28 (13–63)
Female sex, n (%) 12 (71) 12 (60)
Presence of X1 complement gene mutation and/or factor H autoantibody, n/N (%) 13/17 (76)a 14/20 (70)b
Time from diagnosis of aHUS to screening, months, median (range) 9.7 (0.3–235.9) 48.3 (0.7–285.8)
Time from current clinical presentation of aHUS to screening, months, median (range) 0.8 (0.2–3.7) 8.6 (1.2–45.0)
Received PE/PI within 1 week before eculizumab initiation, n (%) 17 (100) 20 (100)
Duration of PE/PI, months, median (range) 0.7 (0.1–3.2) 10.1 (2.4–47.0)
On dialysis before the first dose of eculizumab, n/N (%) 6/17 (35)c 2/20 (10)
X1 Prior kidney transplant, n/N (%) 7/17 (41) 8/20 (40)
Platelet count, 109/l, median (range) 118 (62–161) 218 (105–421)
Patients with platelet count o150109/l, n (%) 15 (88) 3 (15)
LDH level, U/l, median (range) 269 (134–634) 200 (151–391)
LDH4ULNd, n (%) 10 (59) 4 (20)
Hemoglobin level, g/l, median (range) 87 (67–126) 108 (79–131)
Serum creatinine, mmol/l, median (range) 256 (124–787) 234 (106–893)
eGFR, ml/min per 1.73m2
Mean (s.d.) 23 (15) 31 (19)
Median 19 28
Range 5–59 6–72
CKD stage, n (%)
1–2 0 2 (10)
3a/b 5 (29) 8 (40)
4 5 (29) 6 (30)
5 7 (41) 4 (20)
EQ-5D scoree, median (range) 0.8f (0.3 1.0) 0.9 (0.2 1.0)
Abbreviations: aHUS, atypical hemolytic uremic syndrome; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; EQ-5D, EuroQol 5-Dimension
Questionnaire; LDH, lactate dehydrogenase; PE/PI, plasma exchange/plasma infusion; ULN, upper limit of normal.
aCFH (n¼ 4); CFI (n¼ 3); anti-factor H autoantibodies and homozygous deletion of CFHR1 and CFHR3 (n¼ 2); C3 (n¼ 1); CD46 (n¼ 1); CFH and homozygous deletion of
CFHR1 and CFHR3 (n¼ 1); and CFH, CFI, and homozygous deletion of CFHR1 and CFHR3 (n¼ 1).
bCFH (n¼ 3); CFI (n¼ 2); CD46 (n¼ 1); CD46 and CFI (n¼ 1); CFB (n¼ 1); CFH and C3 (n¼ 1); CFI and C3 (n¼ 1); anti-factor H autoantibodies (n¼ 1); homozygous deletion of
CFHR1 and CFHR3 (n¼ 1); CFH and homozygous deletion of CFHR1 and CFHR3 (n¼ 1); and anti-factor H autoantibodies, heterozygous deletion of CFHR3, and homozygous
deletion of CFHR1 (n¼ 1).
cOne of the six patients who had been receiving dialysis within 8 weeks before eculizumab treatment discontinued dialysis 5 weeks before the first dose of eculizumab.
dDefinitions of the ULN for LDH levels varied by trial, gender, and age. For adult patients, ULN was defined as 261U/l in both trials. For adolescent patients, ULN was
defined as 230 261U/l in trial 1 and 230 290U/l in trial 2.
eThe EQ-5D scores range from 0 to 1, with higher scores indicating a better quality of life.
fn¼ 16.
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normalization withdrew from the study within the initial
26-week treatment period.
In trial 2, criteria for TMA event-free status were met by
16 patients (80%) at week 26, 17 patients (85%) at year 1,
and 19 patients (95%) by the 2-year cutoff. Hematologic
normalization was achieved by 18 patients (90%) at all three
time points.
Secondary end points
TMA outcomes. In trial 1, 15 patients (88%) achieved
TMA event-free status by 26 weeks, 1 year, and the 2-year
cutoff. In comparison with a median (range) pretreatment
rate of 0.88 (0.04 1.59), the median (range) TMA
intervention rate decreased to 0 (0 0.31) events/patient
per day at week 26, 1 year, and at the 2-year cutoff (Po0.001
for all time points). Complete TMA response was achieved by
11 patients (65%) at week 26 and by 13 patients (76%) at the
1- and 2-year cutoffs. In trial 2, the median (range) TMA
intervention pretreatment rate (0.23 (0.05 1.09)) decreased
to 0 (0 0) events/patient per day at 26 weeks, 1 year, and at
the 2-year cutoff (Po0.001 for all time points). Complete
TMA response was achieved by five patients (25%) at 26
weeks, by seven patients (35%) at 1 year, and by 11 patients
(55%) at the 2-year cutoff. In both trials, patients with and
without identified complement abnormalities met criteria for
TMA event-free status and complete TMA response at the 2-
year cutoff (Table 4).
Hematologic outcomes. In trial 1, lactate dehydrogenase
(LDH) levels less than or equal to the upper limit of normal
were achieved by 14 patients (82%) at 26 weeks and by 15
patients (88%) at 1 and 2 years. The mean (s.d.) change from
baseline in LDH level was –129 (161) U/l (P¼ 0.0077) at 26
weeks,  27 (42) U/l (P¼ 0.0860) at 1 year, and –205 (107)
U/l (P¼ 0.013) at the 2-year cutoff. The mean (s.d.) change
from baseline in hemoglobin levels was 37 (26) g/l
(Po0.0001) at 26 weeks, 32 (23) g/l (P¼ 0.0005) at 1 year,
and 36 (31) g/l (P¼ 0.0075) at the 2-year cutoff (Figure 4).
In trial 2, 17 patients retained normal platelet counts and
14 maintained normal LDH levels throughout the study. At
the 2-year data cutoff, 18 patients (90%) met the criteria for
normalization of platelet count. Nineteen patients (95%),
including all four with abnormal baseline values, achieved
normal LDH levels at week 26 and at the 1- and 2-year
cutoffs. The mean (s.d.) change from baseline in hemoglobin
levels was 11 (19) g/l (P¼ 0.0231) at 26 weeks, 5 (16) g/l
(P¼ 0.1751) at 1 year, and 14 (16) g/l (P¼ 0.0044) at the 2-
year cutoff (Figure 4).
Renal outcomes. Improvements in eGFR from baseline
levels that were observed at week 26 and at 1 year were
maintained beyond 1 year of eculizumab treatment in trial 1
(Figure 5). Mean changes from baseline in eGFR at week 26,
year 1, and the 2-year cutoff are shown in Table 5. An ad hoc
pairwise comparison showed further improvement in eGFR
between years 1 and 2 in trial 1 (P¼ 0.0285). In trial 2, there
Table 2 |Definitions of primary and secondary efficacy end points
End points Definition
Primary
Trial 1 Platelet count increase: change in platelet count from baseline to week 26 and the proportion of patients with
platelet count normalization (X150109/l; proportion of patients with platelet count normalization sustained
for at least two consecutive measurements for X4 weeks was an additional analysis)
Trial 2 TMA event-free status: absence of all the following forX12 consecutive weeks: (1) a decrease in platelet count
of 425%, (2) plasma exchange/infusion, and (3) new dialysis
Trials 1 and 2 Hematologic normalization: platelet count normalization (X150109/l) and LDHpULN sustained for at least
two consecutive measurements, which span a period of X4 weeks
Secondary
TMA outcomes TMA event-free status (secondary in trial 1 only)
TMA intervention rate: the number of PE/PIs and new dialysis (interventions/patient per day); rate during the
pre-eculizumab period compared with the rate during eculizumab treatment period
Complete TMA response: hematologic normalization plus improvement in renal function (25% reduction from
baseline in serum creatinine in two consecutive measurements for X4 weeks)
Hematologic outcomes Change in hemoglobin X20 g/l from baseline
LDHpULN
Renal function parametersa eGFR increase X15ml/min per 1.73m2b. Serum creatinine decrease X25%. Improvement in proteinuria by
X1 grade. Chronic kidney disease improvement of X1 stage23
Change in HRQoL Change in EQ-5D22 using TTO value set for US population. Attainment of MID in US TTO value (0.06)24
Pharmacokinetics/pharmacodynamics Peak and minimum serum eculizumab concentrations. Hemolysis assay25
Additional Proteinuria: change in grade according to dipstick measurement (negative, trace 1þ , 2þ , 3þ , and 4þ )
Urine protein-to-creatinine ratio
Change in urine protein-to-creatinine ratio from baseline
Abbreviations: eGFR, estimated glomerular filtration rate; EQ-5D, 5-dimension EuroQoL questionnaire; HRQoL, health-related quality of life; LDH, lactate dehydrogenase;
MID, minimally important difference; PE/PI, plasma exchange/plasma infusion; TMA, thrombotic microangiopathy; TTO, time trade-off; ULN, upper limit of normal.
aCriteria were required to be sustained for X2 consecutive measurements, which span a period of X4 weeks.
bFor patients on dialysis, eGFR was calculated with the creatinine value immediately before dialysis or a fixed value of 10ml/min per 1.73m2.
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Table 3 | Efficacy outcomes
Trial 1 Trial 2
Parameter
26-Week
analysis
(N¼ 17)
1-Year
analysisa
(N¼ 17)
2-Year
analysisb
(N¼ 17)
26-Week
analysis
(N¼ 20)
1-Year
analysisa
(N¼ 20)
2-Year
analysisb
(N¼ 20)
Primary end points
Mean change from baseline in platelet count, 109/l (95% CI) 73c (40–105) 91c (67–116)d 75c (54–96) NA NA NA
Normalization of platelet count, n/N (%) 14/17 (82) 15/17 (88) 15/17 (88) 18/20 (90) 18/20 (90) 18/20 (90)
TMA event-free status, n/N (%) 15/17 (88) 15/17 (88) 15/17 (88) 16/20 (80) 17/20 (85) 19/20 (95)
Hematologic normalization, n/N (%) 13/17 (76) 15/17 (88) 15/17 (88) 18/20 (90) 18/20 (90) 18/20 (90)
Secondary end points
TMA and hematologic outcomes
Complete TMA response, n/N (%) 11/17 (65) 13/17 (76) 13/17 (76) 5/20 (25) 7/20 (35) 11/20 (55)
LDHpULN, n/N (%) 14/17 (82) 15/17 (88) 15/17 (88) 19/20 (95) 19/20 (95) 19/20 (95)
Increase in hemoglobin concentration of X20g/l from
baseline, n/N (%)
11/17 (65) 13/17 (76) 13/17 (76) 9/20 (45) 10/20 (50) 13/20 (65)
Mean change in haptoglobin level from baseline, g/l (s.d.) 0.5 (0.44) 0.6 (0.41) 0.9 (0.38) –0.1 (0.52) 0.3 (0.61) 0.5 (0.64)
Renal outcomes
Increase in eGFR of X15ml/min per 1.73m2, n/N (%)e 8/17 (47) 9/17 (53) 10/17 (59) 1/20 (5) 3/20 (15) 8/20 (40)
Decrease in serum creatinine level of X25%, n/N (%)e 11/17 (65) 13/17 (76) 13/17 (76) 3/20 (15) 7/20 (35) 11/20 (55)
Improvement in proteinuria by X1 grade, n/N (%)e,f 12/16 (75) 13/16 (81) 14/16 (88) 6/11 (55) 7/11 (64) 9/11 (82)
Improvement in CKD by X1 stage, n/N (%)e 10/17 (59) 11/17 (65) 12/17 (71) 7/20 (35) 9/20 (45) 12/20 (60)
Abbreviations: CI, confidence interval; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; LDH, lactate dehydrogenase; NA, not applicable;
TMA, thrombotic microangiopathy; ULN, upper limit of normal range.
aMedian (range) treatment duration of 64 (2–90) weeks in trial 1 and 62 (26–74) weeks in trial 2.
bMedian (range) treatment duration of 100 (2–145) weeks in trial 1 and 114 (26–129) weeks in trial 2.
cPo0.001 vs baseline.
dData were from week 60.
eCriteria were required to be sustained for X2 consecutive measurements, which span a period of X4 weeks.
fProteinuria data were not available for all patients.
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Figure 3 |Mean change from baseline in platelet counts over 2 years of eculizumab treatment in trial 1 (P¼ 0.001 at the 2-year cutoff).
Bars represent s.e.
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were no significant differences between changes from baseline
in eGFR at year 2 compared with week 26 or year 1 (P¼NS).
In a subgroup analysis (not shown), changes from baseline in
eGFR were significant (Po0.05) in patients with shorter
disease duration at 26 weeks, 1 year, and 2 years in Trial 1, but
only at 26 weeks in patients with longer disease duration in
trial 2. The absolute mean (s.d.) eGFR was 56 (40) ml/min
per 1.73m2 at 26 weeks, 42 (32) ml/min per 1.73m2 at 1 year,
and 56 (30) ml/min per 1.73m2 at the 2-year cutoff in trial 1,
and 37 (21) ml/min per 1.73m2 at 26 weeks, 39 (20) ml/min
per 1.73m2 at 1 year, and 40 (18) ml/min per 1.73m2 at the
2-year cutoff in trial 2.
Over 2 years of study, discontinuation of dialysis was
observed in both trials. In trial 1, four out of the five patients
(80%) on dialysis at baseline discontinued use, including one
who discontinued before the first dose of eculizumab, and
three who discontinued at a mean of 7.7 days after the
treatment was initiated. New dialysis occurred in one patient
during the 26-week study period, but the patient discon-
tinued the study before the extension phase and was not
included in this analysis. New dialysis also was initiated on
study day 444 in one patient, who subsequently discontinued
the study. Thus, two patients (11.8%) were on chronic
dialysis at the 2-year cutoff. In trial 2, of the two patients
who required dialysis at baseline, one continued dialysis at
the 2-year cutoff and the other received dialysis until renal
transplantation occurred on day 217. During the 2-year study
period, one patient required new dialysis (days 695–696)
during hospitalization for an intestinal hemorrhage and
subsequently died as a result of this complication.
In trial 1, the number of patients who had transplants did
not change between baseline and the 2-year cutoff, and no
patient lost an existing renal graft. In trial 2, no patient
underwent renal transplantation or lost an existing renal graft
Table 4 | Efficacy outcomes at the 2-year cutoff in patients with and without identified complement abnormalitiesa
Trial 1 (N¼ 17) Trial 2 (N¼ 20)
Outcome, n (%)
Patients with identified
abnormalities (n¼ 13)
Patients with no identified
abnormalities (n¼ 4)
Patients with identified
abnormalities (n¼ 14)
Patients with no identified
abnormalities (n¼ 6)
TMA event-free status 12 (92) 3 (75) 14 (100) 5 (83)
Complete TMA response 11 (85) 2 (50) 7 (50) 4 (67)
Abbreviation: TMA, thrombotic microangiopathy.
aIncludes complement gene mutations and polymorphisms and complement factor H autoantibodies.
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Table 5 |Mean change from baseline in eGFR in trial 1 and trial 2
P-value
Time point
Change from baseline in eGFR
(ml/min per 1.73m2)
Compared with
baseline eGFR
Compared with change from
baseline at week 26
Compared with change from
baseline at the 1-year cutoff
Trial 1
Week 26
n 15 — —
Mean (s.d.) 33 (33) 0.0018
Median (range) 20 (1 to 98)
Year 1
n 12 —
Mean (s.d.) 25 (30) 0.0164 0.6299
Median (range) 15 (8 to 82)
Year 2
n 9
Mean (s.d.) 37 (30) 0.0062 0.2099 0.0285
Median (range) 29 (3 to 82)
Trial 2
Week 26
n 20 — —
Mean (s.d.) 6 (6) 0.0003
Median (range) 5 (1 to 20)
Year 1
n 17 —
Mean (s.d.) 7 (10) 0.0057 0.5264
Median (range) 5 (14 to 23)
Year 2
n 15
Mean (s.d.) 8 (17) 0.0959 0.8689 0.7700
Median (range) 11 (42 to 30)
Abbreviations: eGFR, estimated glomerular filtration rate.
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between years 1 and 2 of the study (as reported above, one
patient received a renal transplant on study day 217).
Health-related quality of life. Eculizumab significantly
improved the HRQoL (health-related quality of life), as
measured by changes from baseline on the EuroQoL Group
5-Dimension Self-Report Questionnaire (EQ-5D; Figure 6).22
Improvement began after week 1 in trial 1 (P¼ 0.0398) and
week 3 in trial 2 (P¼ 0.0013), and was maintained over 2
years of treatment (Po0.05 compared with baseline).
Safety
All 17 patients enrolled in trial 1 and 20 patients enrolled in
trial 2 reported one or more adverse events (AEs). Through
the 2-year data cutoff, 17 patients (100%) in trial 1 and 12
patients (60%) in trial 2 reported serious AEs. Table 6 lists
AEs and serious AEs considered possibly, probably, or
definitely associated with eculizumab, as identified by the
investigator, through 2 years of treatment. AEs were reported
with less frequency over time from week 26 to the 2-year
update; no new or cumulative toxicities were observed. There
were no cases of meningococcal infection in either trial.
Among the six patients in trial 1 and two patients in trial 2
who discontinued eculizumab, there were no reported TMA
manifestations within 8 weeks of follow-up. The presence of
nonneutralizing human anti-human antibodies was con-
firmed in one patient in trial 1, who received a single dose of
eculizumab and discontinued following diagnosis of systemic
lupus erythematosus (an exclusion criterion). One patient
in trial 2—who required PI to stop an intestinal hemorrhage
through the introduction of clotting factors—initiated
hemodialysis owing to severe renal failure, and died after
1.9 years of eculizumab treatment owing to complications
from intestinal hemorrhage (as mentioned above). This
was deemed unrelated to eculizumab, although the exact
cause remains unknown.
DISCUSSION
Eculizumab was proven to inhibit the complement-mediated
TMA and improve outcomes for patients with aHUS at 26
weeks and 1 year.21 Here, a 2-year analysis conducted to
examine longer-term outcomes demonstrated that clinical
benefits achieved at earlier time points–including improve-
ments in hematologic parameters, renal function, and
HRQoL—are maintained with ongoing therapy. Terminal
complement activity was inhibited over 2 years in patients
who remained in the studies. In trial 1, the mean change from
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Figure 6 | Least-squares mean change from baseline on patient HRQoL through 2 years of eculizumab treatment in trial 1 and trial 2
(Po0.0001 in both trials at the 2-year cutoff). Bars represent s.e. A change from baseline of 0.06 in EQ-5D score is considered clinically
meaningful.24 EQ-5D, EuroQol 5-Dimension Questionnaire; HRQoL, health-related quality of life.
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baseline in eGFR at year 2 was significantly higher than that
achieved at 1 year, although the P-value was derived from an
ad hoc pairwise analysis and not protocol defined. Thus, it
can only be stated that when compared with baseline the
gains in eGFR at week 26 were maintained at year 2.
Moreover, since the 1-year update, additional patients met
criteria for specific renal parameters (i.e., improvement in
eGFR, serum creatinine, and/or chronic kidney disease stage).
Eculizumab was generally safe, and no cumulative toxicity
was observed over 2 years.
Before the availability of eculizumab, patients with aHUS
could be expected to progress to renal failure, and were at
ongoing risk of serious TMA-related morbidity and death at
rates that varied by genotype.4,6 In the current trials,
eculizumab-treated patients had improvements in chronic
kidney disease over 2 years, and earlier therapy initiation was
significantly correlated with greater gain in eGFR at the 2-
year cutoff in both trials. However, only patients in trial 1,
who were treated earlier than patients in trial 2, showed
ongoing, significant improvement in eGFR between years 1
and 2. This is consistent with a conclusion from the previous
report21 that early treatment initiation may offer patients the
best possible chance to recover renal function. The mech-
anism by which eculizumab leads to gains in renal function is
not known, but it may involve kidney remodeling,26,27
ongoing dissolution of thrombi, maintenance of controlled
Table 6 | Adverse events considered possibly, probably, or definitely associated with eculizumab treatment, as identified by
the investigator
Trial 1 (N¼ 17) Trial 2 (N¼ 20)
Patients, n (%) Patients, n (%)
Adverse event
1 Day–6
months
6–12
Months
12–18
Months
18þ
Months All
Greatest
severity
1 Day–6
months
6–12
Months
12–18
Months
18þ
Months All
Greatest
severity
Serious adverse eventsa
Accelerated hypertension 1 (6) 1 (6) — — 2 (12) Moderate — — — — — —
Asymptomatic bacteriuria — 1 (6) — — 1 (6) Mild — — — — — —
Hypertension 1 (6) — — — 1 (6) Severe — — — — — —
Influenza — — — — — — — — 1 (5) — 1 (5) Severe
Peritonitis — — — — — — 1 (5) — — — 1 (5) Severe
Venous sclerosis at
infusion site
— — — — — — 1 (5) 1 (5) — — 2 (10) Severe
Adverse events
Abnormal blood clotting — — — — — — 1 (5) — — — 1 (5) Mild
Alopecia — — — — — — 1 (5) — — — 1 (5) Mild
Anemia — — — — — — 1 (5) — — — 1 (5) Moderate
Asthenia 1 (6) 1 (6) Moderate — — — — — —
Chest discomfort — — — — — — — — 1 (5) — 1 (5) Mild
Cough or productive
cough
— — — — — — 1 (5) — 1 (5) — 2 (10) Mild
Deafness bilateral — — — — — — — 1 (5) — — 1 (5) Moderate
Dermatitis 1 (6) — — — 1 (6) Mild — — — — — —
Diarrhea 1 (6) — — — 1 (6) Mild — — — — — —
Erythema 1 (6) — — — 1 (6) Moderate — — — — — —
Extravasation — — — — — — 1 (5) — — — 1 (5) Moderate
Fatigue — — — 1 (6) 1 (6) Moderate — — — — — —
Headache 1 (6) — — — 1 (6) Mild 2 (10) — 1 (5) — 3 (15) Moderate (1
patient)
Hematocrit decreased 1 (6) — — — 1 (6) Mild — — — — — —
Hematuria 1 (6) — — — 1 (6) Mild — — — — — —
Hemoglobin decreased 1 (6) — — — 1 (6) Mild — — — — — —
Herpes zoster — 1 (6) — — 1 (6) Mild — — — — — —
Human polyomavirus (BK)
infection
— — — — — — 1 (5) — — — 1 (5) Mild
Hypotension — — — — — — 1 (5) — — — 1 (5) Moderate
Impetigo 1 (6) — — — 1 (6) Moderate — — — — —
Leukopenia 2 (12) — — — 2 (12) Mild 1 (5) 1 (5) — — 2 (10) Mild
Lymphopenia — — — — — — 2 (10) — — — 2 (10) Moderate
(1 patient)
Menorrhagia — — — — — — — — — 1 (5) 1 (5) Mild
Nasal congestion — — — — — — — 1 (5) — — 1 (5) Mild
Nasopharyngitis — — — — — — 1 (5) — — — 1 (5) Mild
Nausea 2 (12) — — — 2 (12) Mild — — — — — —
Pharyngolaryngeal pain — — — — — — — 1 (5) — — 1 (5) Moderate
Pruritus — — — — — — 1 (5) — — — 1 (5) Mild
Pyrexia 1 (6) — — — 1 (6) Mild — — — — — —
Q fever — — — — — — — 1 (5) — — 1 (5) Moderate
Rhinorrhea — — — — — — 1 (5) — — — 1 (5) Moderate
Tremor 1 (6) — — — 1 (6) Moderate — — — — — —
Urinary tract infection 1 (6) — — — 1 (6) Mild — — — — — —
Vertigo 1 (6) — — — 1 (6) Mild — — — — — —
Vomiting 2 (12) — — 1 (6) 3 (18) Mild — — — — — —
aA serious adverse event was defined as any event that results in death, is immediately life threatening, requires hospitalization or prolongation of existing hospitalization,
results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect.
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blood pressure, and/or normalization of endothelial cell
structure and function.28 In addition, no patient with a renal
transplant required a new graft while receiving eculizumab
during the studies, although two patients with grafts
withdrew owing to worsening renal function. This outcome
is distinct from the expected 24% graft loss rate after 1 year in
untreated patients.12
The use of eculizumab was also associated with several
other important clinical benefits,21,29 including the discontinu-
ation of PE/PI and dialysis, and significant improvements in
QoL. In addition to being of limited clinical benefit for
patients with aHUS,4,13 PE/PI must be administered up to
several times per week.13 Dialysis also severely impairs QoL,
due to patient dependence on the procedure and associated
restrictions of daily living.30 In trial 1, most patients on dialysis
at baseline were able to discontinue within B1 week of
eculizumab initiation. In comparison with the natural history
of the disease and supportive care, ongoing therapy with
eculizumab leads to an improvement in the overall well-being
for patients with aHUS.
Current guidelines recommend initiation of eculizumab for
both pediatric and adult patients as soon as a diagnosis of
aHUS is made.7,31 Tests to rule out thrombotic thrombo-
cytopenic purpura (caused by severe deficiency of ADAMTS13
activity) and Shiga-like toxin–producing Escherichia coli
HUS1,2,32 are widely available, give rapid results,7 and are
useful in the differential diagnosis of aHUS.33 Mutational anal-
ysis is available, but it may take months to complete and is not
required to diagnose aHUS and commence treatment;7,31
furthermore, mutations are currently identified in only
50–70% of patients.4,6,7 Although C3 consumption has been
reported in a consanguineous family with DGKE mutations,11
the role of eculizumab has not been established in patients with
this mutation; the identified family had good outcomes with
PE/PI. In both of the current trials, outcomes with eculizumab
were similar for patients with and without identified
complement abnormalities throughout 2 years of study.
Current regulatory guidance notes the potential risk of TMA
manifestations following the discontinuation of eculizu-
mab.15,16 During the limited 8 weeks of follow-up in the
current studies, 0/3 (0%) of patients who discontinued
eculizumab experienced a TMA event. However, one addi-
tional patient experienced a TMA complication following a
respiratory infection 80 days post-discontinuation. This patient
restarted eculizumab with resolution of hemolysis and gradual
renal improvement. Individual case studies19,34–38 and a recent
observational study39 report TMA manifestations following
eculizumab discontinuation in six of the 16 patients (38%; three
with CFH mutations, one with C3, one with no mutation
identified, and one with CFH autoantibody). Although limited,
evidence suggests that close follow-up of patients who
discontinue eculizumab is necessary to prevent poor
outcomes in case of recurrence of TMA.20 Consensus
regarding the optimal length of treatment must be informed
by current treatment guidelines31 and better understanding of
patients’ underlying risk of adverse TMA outcomes.
In conclusion, 2-year analyses of these trials demonstrated
that longer-term eculizumab therapy maintained inhibition
of complement activity, TMA, and improvements in
hematologic parameters and renal function. Furthermore,
eculizumab continued to prevent progression to end-stage
renal disease in the majority of patients with aHUS. Targeting
the underlying complement-mediated etiology represents a
significant advancement in the treatment of aHUS, and the
favorable safety profile of eculizumab is compatible with its
longer-term use. Results from a long-term, observational trial
of patients who previously participated in clinical studies
with eculizumab and data from a global aHUS registry will
provide further insights regarding the effects of ongoing
eculizumab treatment on TMA and renal function.
METHODS
Study design and patient selection
This paper reports 2-year findings from the long-term extension
phases of two open-label, single-arm, multicenter, controlled trials
that evaluated the efficacy and safety of eculizumab in patients with
aHUS. Details of the study design and patient enrollment criteria
were published previously.21 Genetic testing was not required for
study entry, but C3, CFH, CFI, and CD46 mutations, hybrid CFH,
copy-number variation in CFH and CFHRs, and anti-CFH
autoantibodies were identified at study initiation. Patients in trial
1 were required to have clinical evidence of progressing TMA (i.e.,
platelet counto150 109/l and decreased byX25% compared with
an average of three measures obtained before the most recent TMA
presentation) despite X4 PE/PI sessions in the week before
screening. Patients were eligible for trial 2 if they had PE/PI more
than once every 2 weeks but three or more times per week, and did
not have decreases in platelet count425% forX8 weeks before the
first dose of eculizumab. Key exclusion criteria for both trials were
ADAMTS13 activity p5%, as measured at a central laboratory,40
evidence of Shiga toxin–producing Escherichia coli infection, or prior
eculizumab exposure. Patients received immunization and/or
prophylaxis against Neisseria meningitidis, as described previously.21
Patients were eligible for the extension phase of either study
after completing the initial 26-week treatment period. No patients
were excluded, and each patient and primary investigator made
the decision to continue in the extension phase or transfer to
eculizumab obtained via commercial route. During the extension,
patients received a maintenance dose of 1200mg eculizumab every 2
weeks. Patients who discontinued were required to attend follow-up
visits 1, 2, 4, and 8 weeks after the last eculizumab dose.
Assessments
For pharmacodynamic studies, blood samples were collected every
26 weeks during the extension period and at the last visit.
Complement activity was quantified as the degree of in vitro
hemolysis of chicken erythrocytes by patient serum, as determined
by spectrophotometry.25
Efficacy end points were defined previously21 and are described in
Table 2. During the extension study, hematologic (including changes
from baseline in levels of LDH, hemoglobin, and haptoglobin) and
renal parameters (including chronic kidney disease stage and use of
dialysis) were assessed every 4 weeks and at the last study visit.
Measures of renal function were assessed every 8 weeks and at the last
visit of the extension phase. eGFR was calculated using the Schwartz
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formula41 for patients o18 years of age at screening and the
Modification of Diet in Renal Disease equation42 for adults.
The presence of human anti-human antibodies was assessed with
an electrochemiluminescence bridging assay using eculizumab
conjugated to biotin and to SulfoTag (Meso Scale Diagnostics,
LLC; Rockville, MD), which emits light on application of
electrochemical stimulation initiated at the electrode surface of a
streptavidin-coated assay plate. Equimolar quantities of the two
conjugated eculizumab structures were added to the serum-
containing samples (2% (v/v)) and incubated overnight at room
temperature to allow anti-eculizumab bridging complexes to form.
Samples were then transferred to a blocked assay plate and
incubated at room temperature in the dark for 3 h, followed by
washing and measurement of electrochemiluminescence with the
Sector Imager 2400 (Meso Scale Diagnostics, LLC; normalized
against control samples).
Statistical analyses
Methods for statistical analysis have been described previously21 and
were performed by Alexion Pharmaceuticals (Cheshire, CT) using a
SAS System (version 9.2). Baseline demographic and disease charac-
teristics were summarized using descriptive statistics. Efficacy and
safety end points were analyzed based on data obtained through the
2-year cutoff and were compared with baseline values, which were
defined as the last available measurement taken before the first
eculizumab dose. The number and percentage of patients who
achieved end points were reported at week 26, year 1, and year 2.
Wilcoxon signed-rank tests were used to compare pre- and post-
treatment TMA intervention rates. For changes from baseline in
platelet count, a last observation carried forward approach was used
for imputation of missing values through the 2-year cutoff. Least-
squares mean changes from baseline in platelet count, eGFR, and EQ-
5D were analyzed using an analysis of variance model in which
baseline was a covariate and time was considered a categorical
variable. Paired t-tests were used to compare changes from baseline
and to generate pairwise comparisons of changes in eGFR between
week 26, year 1, and year 2. Changes from baseline in eGFR in
subgroups defined by the median duration of the current TMA
manifestation before eculizumab initiation were assessed using t-tests.
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